The final patient has been enrolled in our phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields together with immune checkpoint inhibitors or docetaxel for treatment of patients with advanced stage 4, non-small cell lung cancer following progression while on or after platinum-based therapy.
University of Florida neuro-oncologist Dr. David Tran released updated data from the phase 2 pilot 2-THE-TOP trial testing the safety and efficacy of Tumor Treating Fields together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma.
The final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the safety and efficacy of Tumor Treating Fields together with paclitaxel for treatment in patients with platinum-resistant ovarian cancer.
We reported third quarter financial results for 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth of the company.
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.